Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold?

BMC Medicine

Jasvinder A Singh¹ 

[1] Medicine Service, Birmingham VA Medical Center and Department of Medicine, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294, USA

关键词: stem cell;    gene therapy;    treatment;    novel;    intra-articular;    osteoarthritis;   

Others  :  1126209
DOI  :  10.1186/1741-7015-10-44

 received in 2012-04-24, accepted in 2012-05-02,  发布年份 2012

【 摘 要 】

Osteoarthritis (OA), the most common type of arthritis in the world, is associated with suffering due to pain, productivity loss, decreased mobility and quality of life. Systemic therapies available for OA are mostly symptom modifying and have potential gastrointestinal, renal, hepatic, and cardiac side effects. BMC Musculoskeletal Disorders recently published a study showing evidence of reparative effects demonstrated by homing of intra-articularly injected autologous bone marrow stem cells in damaged cartilage in an animal model of OA, along with clinical and radiographic benefit. This finding adds to the growing literature showing the potential benefit of intra-articular (IA) bone marrow stem cells. Other emerging potential IA therapies include IL-1 receptor antagonists, conditioned autologous serum, botulinum toxin, and bone morphogenetic protein-7. For each of these therapies, trial data in humans have been published, but more studies are needed to establish that they are safe and effective. Several additional promising new OA treatments are on the horizon, but challenges remain to finding safe and effective local and systemic therapies for OA.

Please see related article: http://www.biomedcentral.com/1471-2474/12/259 webcite

【 授权许可】

   
2012 Singh; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Centers for Disease Control and Prevention: Prevalence and Most Common Causes of Disability Among Adults --- United States, 2005. MMWR Morb Mortal Wkly Rep 2009, 58:421-426.
• [2]Centers for Disease Control and Prevention, Arthritis Foundation: A National Public Health Agenda for Osteoarthritis. [http://www.cdc.gov/arthritis/docs/OAagenda.pdf] webcite 2010.
• [3]Buckwalter JA, Saltzman C, Brown T: The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004, (427 Suppl):S6-15.
• [4]Michon M, Maheu E, Berenbaum F: Assessing health-related quality of life in hand osteoarthritis: a literature review. Ann Rheum Dis 2011, 70:921-928.
• [5]Oiestad BE, Holm I, Engebretsen L, Risberg MA: The association between radiographic knee osteoarthritis and knee symptoms, function and quality of life 10-15 years after anterior cruciate ligament reconstruction. Br J Sports Med 2011, 45:583-588.
• [6]Lopez AD, Murray CC: The global burden of disease, 1990-2020. Nat Med 1998, 4:1241-1243.
• [7]Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT: Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol 2002, 156:1021-1027.
• [8]Sinusas K: Osteoarthritis: diagnosis and treatment. Am Fam Physician 2012, 85:49-56.
• [9]Hochberg M, Altman R, April KP, Benkhalti M, Guyatt G, McGowan J, Townheed T, Welch V, Wells G, Tugwell P: American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care & Research 2012, 64:465-474.
• [10]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008, 16:137-162.
• [11]Zhang W, Doherty M, Leeb BF, Alekseeva L, Arden NK, Bijlsma JW, Dincer F, Dziedzic K, Hauselmann HJ, Kaklamanis P, Kloppenburg M, Lohmander LS, Maheu E, Martin-Mola E, Pavelka K, Punzi L, Reiter S, Smolen J, Verbruggen G, Watt I, Zimmermann-Gorska I, ESCISIT: EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis 2009, 68:8-17.
• [12]Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P: OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
• [13]Hunter DJ: Osteoarthritis. Best Pract Res Clin Rheumatol 2011, 25:801-814.
• [14]Weissman IL: Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000, 100:157-168.
• [15]Korbling M, Estrov Z: Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med 2003, 349:570-582.
• [16]Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, Dong A, Du Y, Huang X, Wang J, Lei X, Zheng X: Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Pflugers Arch 2006, 453:43-52.
• [17]Kollar K, Cook MM, Atkinson K, Brooke G: Molecular mechanisms involved in mesenchymal stem cell migration to the site of acute myocardial infarction. Int J Cell Biol 2009, 2009:904682.
• [18]Hu SL, Luo HS, Li JT, Xia YZ, Li L, Zhang LJ, Meng H, Cui GY, Chen Z, Wu N, Lin JK, Zhu G, Feng H: Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells. Crit Care Med 2010, 38:2181-2189.
• [19]Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM: Homing and reparative effect of intra-articular injection of autologus mesenchymal stem cells in osteoarthritic animal model. BMC Musculoskelet Disord 2011, 12:259. BioMed Central Full Text
• [20]Koga H, Shimaya M, Muneta T, Nimura A, Morito T, Hayashi M, Suzuki S, Ju YJ, Mochizuki T, Sekiya I: Local adherent technique for transplanting mesenchymal stem cells as a potential treatment of cartilage defect. Arthritis Res Ther 2008, 10:R84. BioMed Central Full Text
• [21]Noth U, Steinert AF, Tuan RS: Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nat Clin Pract Rheumatol 2008, 4:371-380.
• [22]Murphy JM, Fink DJ, Hunziker EB, Barry FP: Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum 2003, 48:3464-3474.
• [23]Chevalier X: Intraarticular treatments for osteoarthritis: new perspectives. Curr Drug Targets 2010, 11:546-560.
• [24]Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G: Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006, (2):CD005328.
• [25]Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, Loeuille D, Kivitz AJ, Silver D, Appleton BE: Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009, 61:344-352.
• [26]Cohen S, Proudman S, Kivitz Aea: Results of a randomised controlled trial of AMG 108 (a fully monoclonal human antibody to ILR type 1) in patients with osteoarthritis of the knee. Arthritis Rheum 2007, (Suppl 9):1684.
• [27]Yang KG, Raijmakers NJ, van Arkel ER, Caron JJ, Rijk PC, Willems WJ, Zijl JA, Verbout AJ, Dhert WJ, Saris DB: Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage 2008, 16:498-505.
• [28]Baltzer AW, Moser C, Jansen SA, Krauspe R: Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009, 17:152-160.
• [29]Singh JA, Mahowald ML, Noorbaloochi S: Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol 2010, 37:2377-2386.
• [30]Singh JA, Mahowald ML, Noorbaloochi S: Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res 2009, 153:205-216.
• [31]Mahowald ML, Singh JA, Dykstra D: Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res 2006, 9:179-188.
• [32]Boon AJ, Smith J, Dahm DL, Sorenson EJ, Larson DR, Fitz-Gibbon PD, Dykstra DD, Singh JA: Efficacy of intra-articular botulinum toxin type A in painful knee osteoarthritis: a pilot study. PM R 2010, 2:268-276.
• [33]Meng J, Wang J, Lawrence G, Dolly JO: Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci 2007, 120:2864-2874.
• [34]Purkiss J, Welch M, Doward S, Foster K: Capsicin Stimulated Release of Substance P from Cultured Dorsal Root Ganglion Neurons: Involvement of Two Distinct Mechanisms. Biochem Pharmacol 2000, 59:1403-1406.
• [35]Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE: Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008, 101:366-370.
• [36]Rapp DE, Turk KW, Bales GT, Cook SP: Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 2006, 175:1138-1142.
• [37]Birklein F, Schmelz M: Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008, 437:199-202.
• [38]Hunter DJ, Pike MC, Jonas BL, Kissin E, Krop J, McAlindon T: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis. BMC Musculoskelet Disord 2010, 11:232. BioMed Central Full Text
• [39]Sampson S, Reed M, Silvers H, Meng M, Mandelbaum B: Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010, 89:961-969.
• [40]Kruger JP, Hondke S, Endres M, Pruss A, Siclari A, Kaps C: Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res 2012, 30:845-852.
• [41]Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS, Reardon B, Ellsworth JL: Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005, 13:623-631.
• [42]Chen B, Qin J, Wang H, Magdalou J, Chen L: Effects of adenovirus-mediated bFGF, IL-1Ra and IGF-1 gene transfer on human osteoarthritic chondrocytes and osteoarthritis in rabbits. Exp Mol Med 2010, 42:684-695.
• [43]Schmidt MB, Chen EH, Lynch SE: A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthritis Cartilage 2006, 14:403-412.
• [44]Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, Fernandes JC, Martel-Pelletier J: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019.
• [45]Honsawek S, Chayanupatkul M, Tanavalee A, Sakdinakiattikoon M, Deepaisarnsakul B, Yuktanandana P, Ngarmukos S: Relationship of plasma and synovial fluid BMP-7 with disease severity in knee osteoarthritis patients: a pilot study. Int Orthop 2009, 33:1171-1175.
• [46]Ellsworth JL, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, Holdren MS, Lum KD, Moore EE, Raymond F, Ren H, Shea P, Sprecher C, Storey H, Thompson DL, Waggie K, Yao L, Fernandes RJ, Eyre DR, Hughes SD: Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002, 10:308-320.
• [47]Fortier LA, Mohammed HO, Lust G, Nixon AJ: Insulin-like growth factor-I enhances cell-based repair of articular cartilage. J Bone Joint Surg Br 2002, 84:276-288.
• [48]D'Lima D, Hermida J, Hashimoto S, Colwell C, Lotz M: Caspase inhibitors reduce severity of cartilage lesions in experimental osteoarthritis. Arthritis Rheum 2006, 54:1814-1821.
• [49]Huser CA, Peacock M, Davies ME: Inhibition of caspase-9 reduces chondrocyte apoptosis and proteoglycan loss following mechanical trauma. Osteoarthritis Cartilage 2006, 14:1002-1010.
• [50]Hsieh JL, Shen PC, Shiau AL, Jou IM, Lee CH, Teo ML, Wang CR, Chao J, Chao L, Wu CL: Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection. Hum Gene Ther 2009, 20:147-158.
• [51]Ryu JH, Yang S, Shin Y, Rhee J, Chun CH, Chun JS: Interleukin-6 plays an essential role in hypoxia-inducible factor 2alpha-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum 2011, 63:2732-2743.
• [52]Jay GD, Fleming BC, Watkins BA, McHugh KA, Anderson SC, Zhang LX, Teeple E, Waller KA, Elsaid KA: Prevention of cartilage degeneration and restoration of chondroprotection by lubricin tribosupplementation in the rat following anterior cruciate ligament transection. Arthritis Rheum 2010, 62:2382-2391.
• [53]Shimizu S, Asou Y, Itoh S, Chung UI, Kawaguchi H, Shinomiya K, Muneta T: Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis Rheum 2007, 56:3358-3365.
• [54]Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P, Pottie P: Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003, 48:3118-3129.
• [55]Kyrkanides S, Fiorentino PM, Miller JN, Gan Y, Lai YC, Shaftel SS, Puzas JE, Piancino MG, O'Banion MK, Tallents RH: Amelioration of pain and histopathologic joint abnormalities in the Col1-IL-1beta(XAT) mouse model of arthritis by intraarticular induction of mu-opioid receptor into the temporomandibular joint. Arthritis Rheum 2007, 56:2038-2048.
• [56]Jo H, Ahn HJ, Kim EM, Kim HJ, Seong SC, Lee I, Lee MC: Effects of dehydroepiandrosterone on articular cartilage during the development of osteoarthritis. Arthritis Rheum 2004, 50:2531-2538.
• [57]Hu PF, Chen WP, Tang JL, Bao JP, Wu LD: Protective effects of berberine in an experimental rat osteoarthritis model. Phytother Res 2011, 25:878-885.
• [58]Henson FM, Bowe EA, Davies ME: Promotion of the intrinsic damage-repair response in articular cartilage by fibroblastic growth factor-2. Osteoarthritis Cartilage 2005, 13:537-544.
• [59]Martin JA, McCabe D, Walter M, Buckwalter JA, McKinley TO: N-acetylcysteine inhibits post-impact chondrocyte death in osteochondral explants. J Bone Joint Surg Am 2009, 91:1890-1897.